CorporateInformation.com
 
Company Search:
Advanced Search
 
Sponsored Links
 
 
 
 
 
 
 
Epigenomics AG Company Snapshot
Epigenomics AG operates in the Diagnostic substances sector. In addition to historical fundamental analyses, the complete report available to purchase compares Epigenomics AG with three other pharmaceutical manufacturers in Europe: Onxeo SA of France (2016 sales of 4.42 million Euro [US$5.15 million] of which 82% was Operating segment -Rest of the world), Paion AG (4.26 million Euro [US$4.96 million] of which 100% was Pharmaceutical), and Erytech Pharma SA which is based in France (4.14 million Euro [US$4.82 million] of which 100% was Pharmacy).

Sales Analysis. Epigenomics AG reported sales of 4.20 million Euro (US$4.89 million) for the year ending December of 2016. This represents an increase of 101.8% versus 2015, when the company's sales were 2.08 million Euro. Sales of Licenses saw an increase that was more than double the company's growth rate: sales were up 261.5% in 2016, from 156,000.00 Euro to 564,000.00 Euro. Not all segments of Epigenomics AG experienced an increase in sales in 2016: sales of Research and Development fell 79.5% to 74,000.00 Euro.
   
   
 
Company ReportsSubscriptions
 
Looking For More?
Purchace an In-Depth Report
Epigenomics AG
  Stock Performance Chart for Epigenomics AG
 
  Stock Data: Recent Stock Performance:
  Current Price (7/21/2017): 5.08
(Figures in Euro)
1 Week -4.2%   13 Weeks -30.0%  
4 Weeks 1.2%   52 Weeks 3.2%  
 
Epigenomics AG Key Data:
  Ticker: ECX Country: Germany
  Exchanges: FRA Major Industry: Pharmaceuticals & Biotechnology
    Sub Industry: Diagnostic Substances
  2016 Sales 4,201,000
(Year Ending Jan 2017).
Employees: 45
  Currency: Euro Market Cap: 115,426,915
  Fiscal Yr Ends: December Shares Outstanding: 22,735,260
  Share Type: STAMMAKTIE Closely Held Shares: 3,249,824
 
 
Sponsored Links
 
 
 
 
Feedback | Terms and Conditions | Privacy Policy | Site Index
 
CorporateInformation® website and selected data Copyright © 2000 - by The Winthrop Corporation. All Rights Reserved. Except for quotations by established news media, no pages on this site may be reproduced, stored in a retrieval system, or transmitted for commercial purposes, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without prior written permission. Information is believed reliable, but accuracy, completeness and opinions are not guaranteed.